glp 1 drug mechanism of action Frontiers Cardiovascular Protection with a Long-Acting
Description
N Engl J Med 2015
Pfizer is investing a lot in research and development too, mainly to make healthcare outcomes better and to upgrade treatment technologies
These include GLP1/glucagon dual agonists (AstraZeneca, Boehringer Ingelheim, Hanmi Pharma, Eli Lilly) , GIP/GLP1/glucagon tri-agonists (Hanmi Pharmaceuticals, Eli Lilly), or solo GIPR agonists (Eli Lilly, Zealand Pharma)
1388 Dose increment-associated liraglutide-induced acute pancreatitis
10.1016/j.japh.2023.10.002
and Metabolism 91 (5), 19161923
